In the present study, we demonstrated that IGFBP-3 is involved in decreased DSB-DNA damage which is mediated by DNA-PKcs activation with the formation of the aforementioned complex and that high tumour IGFBP-3 levels are associated with reduced chemoradiotherapy efficacy and poor prognosis in OSCC. This evidence concerns the gene IGFBP3 and neoplasm.